Drugdocs | Anthim®

Drug updated on 4/26/2024

Dosage Form	Injection (intravenous; 600 mg/6 mL)
Drug Class	Monoclonal antibody against B. anthracis
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Obiltoxaximab (Anthim) is indicated for the treatment of inhalational anthrax in adults and pediatric patients, used in combination with appropriate antibacterial drugs. It is also used for prophylaxis when alternative therapies are not available or suitable.
A single systematic review/meta-analysis was reviewed to gather information about this drug.
The efficacy of obiltoxaximab has been demonstrated through studies involving New Zealand White rabbits and cynomolgus macaques, showing higher survival rates post-exposure to inhalational anthrax compared to control groups.
Safety evaluations conducted on healthy human volunteers indicate that obiltoxaximab is well-tolerated with a relatively low incidence of adverse events, suggesting a favorable safety profile, especially considering the severity of inhalational anthrax and the limited treatment options available.
While no direct comparison between obiltoxaximab and other antitoxins or antibacterial drugs was provided in the study, it acknowledges its value as an addition to existing treatments, particularly where alternatives are unsuitable or unavailable.
Although specific data regarding different age groups were not detailed within the study, both adult and pediatric patients can be treated with obiltoxaximab, indicating its wide-ranging suitability across various ages, which is crucial during public health responses to incidents related to exposure to Anthrax.

Document Title	Year	Source
Anthim (obiltoxaximab) Prescribing Information.	2019	Therapeutics, Inc., Parsippany, NJ

Document Title	Year	Source
Obiltoxaximab: Adding to the treatment arsenal for bacillus anthracis infection	2017	The Annals of Pharmacotherapy

Document Title	Year	Source
Virginia Department of Health Anthrax: Guidance for Healthcare Providers Key Medical and Public Health Interventions after Identification of a Suspected Case.	2023	Virginia Department of Health
Use of anthrax vaccine in the united states: Recommendations of the advisory committee on immunization practices, 2019.	2019	Morbidity and Mortality Weekly Report- Recommendations and Reports